| Summary: | 碩士 === 國立陽明大學 === 生物藥學研究所 === 102 === Alzheimer’s disease (AD) is a global problem. In 2050, expectation of patients with AD will increase to 114 million. This will cause many social and economic burdens. Several drugs have been used for the treatment of AD in clinical; however, these drugs can only control the symptom, but not the cure. Many studies indicate that the deposition of β-amyloid (Aβ) is related in the pathogenesis of AD. Therefore, the companies and scientists were developed Aβ target drugs, but recent reports of clinical trial indicated these drugs cannot ameliorate symptom. The small molecular drug is difficult development for treatment of AD. In this study, we hope to find the treatment of AD from herbal medicines including two partially purify fractions HH-F3 and EH7-F7. Both extracts were found to reduce Aβ production, aggregation and toxicity in vitro. In animal model, HH-F3 not only reduces Aβ production and aggregation, but also up-regulates Aβ-clearance associated protein. The HH-F3 and EH7-F7 possess potential for treatment of AD. On the other hand, thioridazine was discovered to possess similar cellular stimulated activity as HH-F3 and EH7-F7 through the gene profiling of connectivity map. Thioridazine was also found to possess the activity to reduce Aβ accumulation, and the mechanism of its activity is related to autophagy.
|
|---|
